Effects of paclitaxel with or without cremophor EL on cellular clonogenic survival and apoptosis

European Journal of Cancer

Volumn 35, Issue 2, 1999, Pages 284-288

  Engblom, P ^a,b   Pulkkinen, J O ^a   Rantanen, V ^a   Hirvonen, H ^a   Kulmala, J ^a   Grenman R ^a   Grenman S ^a  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

Author keywords

Apoptosis; Cellular survival; Clonogenic assay; Cremophor EL; Multidrug resistance; Paclitaxel

Indexed keywords

CREMOPHOR; PACLITAXEL;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL SURVIVAL; CLONOGENESIS; CONTROLLED STUDY; HUMAN; HUMAN CELL; LARYNX CARCINOMA; MICROSCOPY; NORTHERN BLOTTING; OVARY ADENOCARCINOMA; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; VIDEORECORDING;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL SURVIVAL; GLYCEROL; HUMANS; PACLITAXEL; TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY; VEHICLES;

EID: 0033083319     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(98)00298-6     Document Type: Article

References (24)

1. Cremophor EL® BASF Technical Leaflet, MEF 074e, 1986.
2. Schuurhuis G.J., Broxterman H.J., Pinedo H.M. The polyoxyethylene castor oil cremophor EL modifies multidrug resistance. Br J Cancer. 62:1990;591-594.
3. Woodcock D.M., Jefferson S., Linsenmeyer M.E., et al. Reversal of the multidrug resistance phenotype with cremophor EL, a common vehicle for water-insoluble vitamins and drugs. Cancer Res. 50:1990;4199-4203.
4. Chervinsky D.S., Brechter M.L., Hoelcle M.J. Cremophor EL enhances taxol efficacy in a multi-drug resistant C1300 neuroblastoma cell line. Anticancer Res. 13:1993;93-96.
5. Fjällskog M.L., Frii L., Bergh J. Paclitaxel induced cytotoxicity - the effects of cremophor EL (castor oil) on two human breast cancer cell lines with acquired multidrug resistant phenotype and induced expression of the permeability glycoprotein. Eur J Cancer. 30A:1994;687-690.
6. Liebmann J., Cook A.J., Lipschultz C., Teague D., Fisher J., Mitchell J.B. The influence of cremophor EL on the cell cycle effects of paclitaxel (Taxol®) in human tumour cell lines. Cancer Chemother Pharmocol. 33:1994;331-339.
7. Buckingham L., Balasubramanian M., Emanuele M., Clodfelter K., Coon J. Comparison of solutol HS 15, Cremophor EL and novel ethoxylated fatty acid surfactants as multi-drug resistance modification agents. Int J Cancer. 62:1995;436-442.
8. Linsenmeyer M.E., Jefferson S., Wolf M. Levels of expression of the mdr-1 gene and glutathione s-transferase genes 2 and 3 and response to chemotherapy in multiple myeloma. Br J Cancer. 65:1992;471-475.
9. Nygren P., Csôka K., Jonsson B., et al. The cytotoxic activity of taxol in primary cultures of human tumour cells from patients is partly mediated by cremophor EL. Br J Cancer. 71:1995;478-481.
10. Elomaa L., Joensuu H., Kulmala J., Klemi P., Grènman R. Squamous cell carcinoma of the larynx is highly sensitive to paclitaxel in vitro. Acta Otolaryngol (Stockh). 115:1995;340-344.
11. Pulkkinen J.O., Elomaa L., Joensuu H., Martikainen P., Servomaa K., Grènman R. Paclitaxel-induced apoptotic changes followed by time-lapse video microscopy in cell lines established from head and neck cancer. J Cancer Res Clin Oncol. 122:1996;214-218.
12. Ormerod M.G., O'Neil C.F., Robertson D., Harrap K.R. Paclitaxel induces apoptosis in a human ovarian carcinoma cell line without concomitant internucleosomal degradation of DNA. Exper Cell Res. 211:1994;231-237.
13. Havrilesky L.J., Elbendary A., Hurteau J.A., Whitaker R.S., Rodriguez G.C. The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2. Oncogene. 11:1995;1217-1223.
14. Chirgwin J., Przybla A.E., MacDonald R.J., Rutter W.J. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry. 18:1979;5294-5299.
15. Freinberg A.P., Vogelstein B. A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Anal Biochem. 132:1983;6-13.
16. Grènman R., Burk D., Virolainen E., Buick R.N., Church J., Schwartz D.R., Carey T.E. Clonogenic cell assay for anchorage-dependent squamous carcinoma cell lines using limiting dilution. Int J Cancer. 44:1989;131-136.
17. Rantanen V., Grènman S., Kulmala J., Grènman R. Comparative evaluation of cisplatin and carboplatin sensitivity in endometrial adenocarcinoma cell lines. Br J Cancer. 69:1994;482-486.
18. Engblom P., Rantanen V., Kulmala J., Grènman S. Paclitaxel and cisplatin sensitivity of ovarian carcinoma cell lines tested with the 96-well plate clonogenic assay. Anticancer Res. 16:1996;1743-1748.
19. Huizing M.T., Keung A.C.F., Rosing H. Pharmacokinetics of paclitaxel and metabolites in a randomised comparative study in platinum-pre-treated ovarian cancer patients. J Clin Oncol. 11:1993;2127-2135.
20. Holzmayer T., Hilsenbeck S., Von Hoff D.D. Clinical correlates of MDRI (P-glycoprotein) gene expression in ovarian and small-cell lung carcinomas. J Natl Cancer Inst. 84:(19):1992;1486-1491.
21. Kristensen G., Baekelandt M., Holm R. PGP expression as a possible marker for response to cisplatin-epirubicin as a first-line treatment in advanced ovarian cancer. Gynecol Oncol. 56:1995;110-115.
22. Wetanabe T., Nakayama Y., Naito M., Oh-hara T., Itoh Y., Tsuruo T. Cremophor EL reversed multidrug resistance in vitro but not in tumour-bearing mouse models. Anti-Cancer Drugs. 7:1996;825-832.
23. Csóka K., Dhar S., Fridborg H., Larsson R., Nygren P. Differential activity of cremophor EL and paclitaxel in patient's tumour cells and human carcinoma cell lines in vitro. Cancer. 79:1997;1225-1233.
24. Lopes N.M., Adams E.G., Pittis T.W., Bhuyan B.K. Cell kill kinetics and cell cycle effects of taxol on human and hamster ovarian cell lines. Cancer Chemother Pharmacol. 32:1993;235-241.